First Light Asset Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
First Light Asset Management reported a $1.6 bn portfolio of 31 positions to the SEC as of the end of Q2 2026. Its largest positions are NEO, SIBN, AXGN. During the quarter it opened Trevi Therapeutics and Tactile Systems Technology.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then First Light Asset Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Aug 31, 2026 · filed Sep 4, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Jul 7, 2026 · filing ↗
What changed this quarter
33 positions with a change (2 new, 17 added to, 9 trimmed, 5 sold); also, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Enliven Therapeutics+574%more sharesIncreased0.7% → 4.2%
- Axogen−31%fewer sharesReduced11.9% → 7.7%
- Apogee Therapeutics+61%more sharesIncreased4.3% → 7.5%
- Si-bone+52%more sharesIncreased6.1% → 8.1%
- Trevi Therapeutics+2.4 ppof portfolioNew— → 2.4%
- Neogenomics+26%more sharesIncreased6.5% → 10.9%
- GeneDx Holdings+223%more sharesIncreased1.4% → 3.3%
- Palvella Therapeutics−21%fewer sharesReduced11.0% → 7.2%
- Tandem Diabetes Care+157%more sharesIncreased2.3% → 3.1%
- Guardant Health+58%more sharesIncreased2.3% → 4.0%
- Twist Bioscience−17%fewer sharesReduced3.7% → 4.6%
- Tactile Systems Technology+0.8 ppof portfolioNew— → 0.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- NeogenomicsNEO10.9%
- Si-boneSIBN8.1%
- AxogenAXGN7.7%
- Apogee Therapeutics7.5%
- Palvella TherapeuticsPVLA7.2%
- Twist BioscienceTWST4.6%
- Enliven TherapeuticsELVN4.2%
- Guardant HealthGH4.0%
- 908 DevicesMASS3.3%
- Amylyx PharmaceuticalsAMLX3.3%
- GeneDx HoldingsWGS3.3%
- Simulations PlusSLP3.1%
- Tandem Diabetes CareTNDM3.1%
- Crinetics PharmaceuticalsCRNX3.1%
- NeuropaceNPCE2.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 94%
- ● Information Technology 6%
How its portfolio changed (8 quarters)
Q2 2026: 31
Q2 2026: 61%
Q2 2026: 17.3%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 24, 2026 (high confidence).
The data, as reported: FIRST LIGHT ASSET MANAGEMENT, LLC (CRD 168899): 7.B private funds: 3 hedge (gross assets $975M); 5.D assets by client type: pooled vehicles 69%, high net worth 25% (of $1.4 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Triodos Investment Management BVInvestment firm · $1.6 bn
- MPM BioimpactInvestment firm · $1.6 bn
- Kopernik Global InvestorsInvestment firm · $1.6 bn
- Atalan Capital PartnersInvestment firm · $1.6 bn
- No Street GPInvestment firm · $1.7 bn
- Strategy CapitalInvestment firm · $1.6 bn